Biocept Stock Price. Everything You Need To Know About The Biocept Stock!

Biocept, Inc. is a San Diego-based oncology laboratory service company that specializes in developing and marketing novel laboratory products for the detection of rare cells, including circulating tumor cells. The company, which has been in operation since 2014, currently has 174 full-time employees and is publicly traded.

Biocept’s main focus is on developing and commercializing clinical diagnostic laboratory assays that are designed to identify tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid. Its flagship product, CNSide, is a branded and trademarked technology that is used for this purpose. Additionally, the company’s Target Selector technologies enable the detection of specific gene mutations, such as EGFR, KRAS, or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells isolated from blood.

With its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach, Biocept’s technology provides both high-sensitivity and specificity. This makes it applicable to a range of diagnostic applications in patients with metastatic carcinoma. As such, Biocept is a crucial player in the liquid biopsy market, providing blood-based liquid biopsy technology that helps to revolutionize cancer diagnostics.

If you’re interested in the stock market, it’s important to keep an eye on companies like Biocept. By researching companies like this, you can stay up-to-date with industry trends and make informed investment decisions. Be sure to check out stock prices and other key metrics such as market cap and premarket trading activity to get a sense of how the company is performing. By doing your due diligence and keeping abreast of the latest developments in the field, you’ll be well-positioned to make the most of your investments.